Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024)

Krystal Biotech has disclosed Restructuring Costs across 3 years of filings, most recently posting $12.5 million for Q3 2024.

• Restructuring Costs for Q3 2024 came in at $12.5 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $12.5 million (down 85.71% YoY), and the FY2024 annual result was $37.5 million, up 200.0% from the prior year.
• Restructuring Costs came in at $12.5 million for Q3 2024 at Krystal Biotech, down from $37.5 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $37.5 million in Q4 2023 to a low of $12.5 million in Q1 2023.
• The 3-year median for Restructuring Costs is $12.5 million (2023), against an average of $21.4 million.
• Across the five-year window, Restructuring Costs plunged 50.0% in 2023 and surged 200.0% in 2024, its largest moves.
• Krystal Biotech's Restructuring Costs stood at $25.0 million in 2022, then surged by 50.0% to $37.5 million in 2023, then slumped by 66.67% to $12.5 million in 2024.
• The last three Restructuring Costs figures came in at $12.5 million (Q3 2024), $37.5 million (Q2 2024), and $12.5 million (Q1 2024), per Business Quant data.